New insider activity at Trulieve Cannabis ( (TSE:TRUL) ) has taken place on August 13, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Susan Thronson recently made a significant investment in Trulieve Cannabis by purchasing 3,968 shares of the company’s stock, valued at $24,998. This move indicates a strong vote of confidence in the company’s future prospects.
Recent Updates on TSE:TRUL stock
Trulieve Cannabis has recently reported its Q2 2025 earnings, revealing a revenue of $302 million and a gross margin of 61%. Despite a net loss of $14 million, the company showed strong cash flow from operations and expanded its retail presence with new dispensaries and product lines. Analysts have maintained a positive outlook on Trulieve’s stock, with a Buy rating and increased price targets, driven by the company’s robust operational capabilities, strategic market expansion, and product innovation. However, challenges such as pricing compression and profitability concerns persist, influencing some analysts to adopt a more cautious stance. The company’s focus on federal cannabis reform and strategic growth initiatives are seen as potential catalysts for future success.
Spark’s Take on TSE:TRUL Stock
According to Spark, TipRanks’ AI Analyst, TSE:TRUL is a Neutral.
Trulieve Cannabis’s overall score reflects strong revenue growth and bullish technical indicators, but is tempered by profitability challenges and a negative valuation. The earnings call provided positive insights into operational improvements, though concerns about pricing pressure and projected revenue declines remain.
To see Spark’s full report on TSE:TRUL stock, click here.
More about Trulieve Cannabis
YTD Price Performance: 25.21%
Average Trading Volume: 472,342
Technical Sentiment Signal: Buy
Current Market Cap: $1.44B